TSE:4503Pharmaceuticals
FDA Expands PADCEV Combo Approval and It Might Change the Case for Investing in Astellas Pharma (TSE:4503)
On November 21, 2025, Pfizer Inc. and Astellas Pharma Inc. announced that the FDA approved PADCEV (enfortumab vedotin-ejfv) combined with pembrolizumab as a perioperative treatment for adult patients with muscle-invasive bladder cancer ineligible for cisplatin-containing chemotherapy, following positive Phase 3 results.
This approval expands treatment options for a challenging patient group and highlights continued clinical progress in antibody-drug conjugates and immuno-oncology...